Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 09, 2023

SELL
$0.68 - $1.59 $18,020 - $42,136
-26,501 Reduced 42.12%
36,413 $57,000
Q3 2022

Nov 14, 2022

BUY
$0.96 - $9.68 $60,397 - $609,007
62,914 New
62,914 $60,000
Q2 2022

Aug 15, 2022

SELL
$0.81 - $1.34 $158,666 - $262,485
-195,885 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$1.23 - $1.95 $24,912 - $39,495
-20,254 Reduced 9.37%
195,885 $257,000
Q3 2021

Nov 16, 2021

SELL
$2.08 - $3.6 $833,609 - $1.44 Million
-400,774 Reduced 64.96%
216,139 $470,000
Q2 2021

Aug 16, 2021

BUY
$3.36 - $10.56 $19,504 - $61,300
5,805 Added 0.95%
616,913 $2.16 Million
Q1 2021

May 17, 2021

BUY
$9.26 - $14.36 $164,920 - $255,751
17,810 Added 3.0%
611,108 $6.03 Million
Q4 2020

Feb 16, 2021

BUY
$9.84 - $14.26 $202,861 - $293,984
20,616 Added 3.6%
593,298 $6.43 Million
Q3 2020

Nov 13, 2020

BUY
$10.3 - $21.64 $1.24 Million - $2.6 Million
120,286 Added 26.59%
572,682 $5.9 Million
Q2 2020

Aug 14, 2020

BUY
$8.53 - $25.64 $573,557 - $1.72 Million
67,240 Added 17.46%
452,396 $9.45 Million
Q1 2020

May 15, 2020

BUY
$7.98 - $16.32 $445,132 - $910,345
55,781 Added 16.94%
385,156 $3.76 Million
Q4 2019

Feb 07, 2020

BUY
$5.12 - $12.22 $39,813 - $95,022
7,776 Added 2.42%
329,375 $3.8 Million
Q3 2019

Nov 08, 2019

BUY
$5.24 - $15.89 $1 Million - $3.05 Million
191,657 Added 147.49%
321,599 $1.75 Million
Q2 2019

Aug 09, 2019

BUY
$5.1 - $11.89 $19,431 - $45,300
3,810 Added 3.02%
129,942 $1.55 Million
Q1 2019

May 14, 2019

BUY
$3.03 - $6.02 $37,738 - $74,979
12,455 Added 10.96%
126,132 $661,000
Q2 2018

Aug 08, 2018

BUY
$5.3 - $6.9 $602,488 - $784,371
113,677 New
113,677 $603,000

Others Institutions Holding ADVM

About Adverum Biotechnologies, Inc.


  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $681M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.